TransMedics Group (NASDAQ:TMDX) Stock Gets Price Target Trim from Canaccord Genuity Group

TransMedics Group (NASDAQ:TMDX) had its target price lowered by Canaccord Genuity Group from $95.00 to $94.00 in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities analysts also recently issued reports about the stock. Needham & Company LLC reaffirmed a “buy” rating on shares of TransMedics Group in a report on Friday, September 11th. Zacks Research downgraded shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. UBS Group lowered their target price on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a report on Wednesday, August 5th. Barclays started coverage on shares of TransMedics Group in a report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price target on the stock. Finally, TD Cowen reaffirmed a “buy” rating and issued a $120.00 price objective on shares of TransMedics Group in a research report on Tuesday, September 8th. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $115.60.

TransMedics Group Stock Up 1.3%

TMDX stock opened at $76.52 on Tuesday. The firm has a market capitalization of $2.64 billion, a PE ratio of 38.33, a P/E/G ratio of 1.04 and a beta of 1.94. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. TransMedics Group has a twelve month low of $60.10 and a twelve month high of $156.00. The stock’s 50 day moving average is $85.81 and its 200-day moving average is $82.99.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.06). The company had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%. The company’s quarterly revenue was up 20.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.92 EPS. Sell-side analysts expect that TransMedics Group will post 1.46 EPS for the current fiscal year.

Insider Activity

In other TransMedics Group news, Director David Weill acquired 1,336 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were bought at an average price of $81.63 per share, for a total transaction of $109,057.68. Following the completion of the transaction, the director owned 16,392 shares of the company’s stock, valued at approximately $1,338,078.96. This represents a 8.87% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 6.90% of the company’s stock.

Institutional Trading of TransMedics Group

A number of large investors have recently modified their holdings of TMDX. HB Wealth Management LLC raised its stake in TransMedics Group by 0.7% in the first quarter. HB Wealth Management LLC now owns 14,843 shares of the company’s stock valued at $1,476,000 after purchasing an additional 107 shares in the last quarter. Total Clarity Wealth Management Inc. lifted its position in TransMedics Group by 5.1% during the first quarter. Total Clarity Wealth Management Inc. now owns 2,322 shares of the company’s stock valued at $231,000 after purchasing an additional 112 shares during the last quarter. Values First Advisors Inc. grew its stake in TransMedics Group by 3.1% in the 1st quarter. Values First Advisors Inc. now owns 5,944 shares of the company’s stock worth $591,000 after buying an additional 181 shares in the last quarter. Plan A Wealth LLC grew its stake in TransMedics Group by 3.9% in the 3rd quarter. Plan A Wealth LLC now owns 5,370 shares of the company’s stock worth $448,000 after buying an additional 203 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its stake in TransMedics Group by 95.0% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 425 shares of the company’s stock worth $45,000 after buying an additional 207 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant.

The company offers OCS solutions for heart, lung and liver transplantation.